SCHEMBL10148327

SCHEMBL10148327

NCCNC(=O)c1sc2ccccc2c1Cl

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OGG1 O15527 1/20 0.71
HDAC1 Q13547 1/20 0.64
HDAC8 Q9BY41 1/20 0.64
HDAC6 Q9UBN7 1/20 0.64
CA1 P00915 1/20 0.63
CA2 P00918 1/20 0.63
CA9 Q16790 1/20 0.63
LMNA P02545 2/20 0.61
RAB9A P51151 8/20 0.60
NPC1 O15118 6/20 0.60
SMN1; SMN2 Q16637 5/20 0.60
MAPT P10636 4/20 0.60
ALDH1A1 P00352 3/20 0.60
GAA P10253 2/20 0.60
HPGD P15428 2/20 0.60
TP53 P04637 2/20 0.60
PRNP P04156 1/20 0.60
PKM P14618 1/20 0.60
KMT2A Q03164 1/20 0.58
RXFP1 Q9HBX9 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15931659 0.83 CA1 (0.74) OGG1HDAC1HDAC8HDAC6CA1
SCHEMBL6477287 0.83 OGG1 (1.00) OGG1HDAC1HDAC8HDAC6LMNA
SCHEMBL25774012 0.80 OGG1 (0.67) OGG1HDAC1HDAC8HDAC6LMNA
SCHEMBL9024708 0.80 SENP5 (0.55) OGG1LMNARAB9ANPC1SMN1; SMN2
SCHEMBL1886020 0.79 HDAC1 (1.00) OGG1HDAC1HDAC8HDAC6LMNA
SCHEMBL7984062 0.77 HDAC1 (0.79) OGG1HDAC1HDAC8HDAC6LMNA
SCHEMBL8631382 0.77 OGG1 (0.70) OGG1HDAC1HDAC8HDAC6LMNA
SCHEMBL7987880 0.76 RAB9A (0.61) OGG1HDAC1HDAC8HDAC6LMNA
SCHEMBL10998217 0.76 LMNA (0.59) OGG1HDAC1HDAC8HDAC6CA1
SCHEMBL11086844 0.76 SMN1; SMN2 (0.66) OGG1HDAC1HDAC8HDAC6CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND DGAT1, DGAT2, DIMT1 OGG1 2140/4885HDAC1 1223/4885HDAC8 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.